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Nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), cytokines, stem cell factor etc. are some promising 
biomarkers for overactive bladder (OAB). To diagnose OAB urinary NGF/Creatinine (Cr) has 87.5% sensitivity and 100% 
specificity, and BDNF/Cr has 87.5% sensitivity and 83.3% specificity. In female OAB patient, urinary MCP-1 (monocyte 
chemotactic protein) was very high. In plasma 5 biomarkers IL-4 (Interleukin), TNF-α (Tumor necrosis factor), MIP-1β 
(macrophage inflammatory protein), SAA (Serum amyloid A), and Tie2 (Tyrosine kinase receptor) could significantly 
differentiate between OAB patients and control individuals. c-kit ligand, stem cell factor (SCF) found to be significantly more 
on overactive bladder than control. mRNA expression of connexin (Cx) and transient receptor potential (TRP) channel on 
urothelial cells from urine showed positive correlations of Cx26 vs urgency score, Cx40 vs nocturia, TRPM2 (Transient receptor 
potential melastatin 2) vs intermittency, TRPV1 (Transient receptor potential cation channel subfamily V member 1) vs urgency 
incontinence, and negative correlation of Cx40 vs intermittency. In plasma measurement of miR-98-5p (upregulation) + miR-
139-5p (downregulation) seems to be a good biomarker (AUC = 0.839). 
Keywords: Brain derived neurotrophic factor, Cyclooxygenase, MCP-1, Nerve growth factor, Nocturia, Stem cell factor, 
Urinary creatinine 
Introduction 
Overactive bladder (OAB) is a condition of urinary 
urgency, usually accompanied by increased daytime 
frequency and/or nocturia, with urinary incontinence 
(OAB-wet) or without (OAB-dry), in the absence of 
urinary tract infection or other detectable diseases. 
(International Continence Society, ICS)1 Urinary 
frequency is defined as micturiting 8 or more times in 
a day (24 h). Nocturia is defined as waking to 
micturate 1 or more times per night2.  
 
Prevalence 
EPIC study [European Prospective Investigation 
into Cancer and Nutrition (EPIC) study] one of the 
largest population-based surveys, revealed OAB 
prevalence as 11.8%, with similar rates in men and 
women3. NOBLE study (National Overactive Bladder 
Evaluation) in the USA revealed the prevalence of 
16% (men) and 16.9% (women). With increasing age, 
women faced more urgency incontinence  
> 44 years whereas for men it is > 64 years4. In Asia, 
the overall prevalence of OAB is 53.1% and 
prevalence of urgency incontinence in the female is 
11.4%5. In India the prevalence of urgency urinary 
incontinence in the female is 38%6. 
 
Patho-physiology 
Detrusor muscle over activity is the root cause of 
OAB syndrome. Detrusor over activity (DO) may be 
due to - neurogenic, myogenic, or autonomous 
bladder activity7.  
Myogenic theory: Partial denervation of the 
detrusor myocytes may alter the properties 
(supersensitivity to neurotransmitters) of detrusor 
smooth muscle and leads to increased excitability and 
ability of activity to spread between cells. As a result, 
there are coordinated myogenic contractions of the 
whole detrusor8,9. 
Neurogenic theory: Cortical injury of the brain may 
cause the excitability of the bladder by reducing 
suprapontine inhibition. Spinal cord axonal pathways 
injury can lead to the emergence of primitive spinal 
bladder reflexes triggered by C-fiber bladder afferent 
neurons. Hence there could be bladder excitability10,11. 
————— 
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Abbreviation: AUC, Area under curve; Cr, Creatinine; DO, 
Detrusor Overactivity; ELISA, Enzyme-linked immunosorbent 
assay; MCP 1, Monocyte chemotactic protein 1; ROC, Receiver 
operating characteristic 
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Autonomous bladder theory: Detrusor muscle is 
arranged into modules which are circumscribed areas 
activated during the storage phase of the micturition 
cycle. The modules might be controlled by a 
peripheral myovesical plexus, comprised of 
intramural ganglia and interstitial cells. DO results 
from a shift in the balance of excitation and inhibition 
in smooth muscle modules12. 
The women suffering from OAB literary feel afraid 
of going out of home – if urgency comes and no toilet 
nearby! This has become a nightmare for them. 
Slowly they become depressed. The bothersome 
discomfort faced by the women suffering from 
overactive bladder has urged the researcher to seek 
for any biomarker (biological marker) which may 
diagnose or predict the possibility of overactive 
bladder and respective care may be addressed to that 
women. 
 
Overactive bladder biomarker 
Biomarkers are used to envisage the health status in 
individuals or across the populations so as to plan 
appropriate therapeutic intervention13. Recent years 
have seen the onset of novel technologies like 
proteomics, metabolomics, lipidomics, and urinomics, 
to develop many novel biomarkers14. Due to the 
complex pathophysiology of overactive bladder 
(OAB) researchers are searching biomarkers 
connected with bladder inflammation or nerve 
growth. Nerve growth factor (NGF), the brain 
derived neurotrophic factor (BDNF), cytokines, stem 
cell factor etc. are showing promising results15. 
BDNF (Brain derived neurotrophic factor), 
NGF (Nerve growth factor) 
BDNF and NGF belongs to neurotrophin family of 
growth factors. They are dimeric molecules with 50% 
identical structures16. BDNF involves to axonal 
growth, pathfinding and in the modulation of 
dendritic growth and morphology17 –– thus may cause 
detrusor overactivity (Fig. 1). 
The urinary levels of NGF/Cr were higher in OAB 
patients than in controls P <0.001)19,20. BDNF, NGF 
etc. levels are adjusted according to the urinary 
creatinine (Cr) level. This is done as there is varying 
hydration level which may give otherwise false data if 
not corrected21. Urinary creatinine assessment can be 
done by the commercially available kit e.g. Cayman 
(Ann Arbor, MI, USA) which has a dynamic 
sensitivity of 0-15 mg/dl Cr. Absorbance level per 
sample can be measured at 500 nm, with 
concentration calculation is done as per the standard 
curve. Before treatment urine NGF/Cr ratio and 
BDNF/Cr ratio were significantly higher in OAB22,23. 
NGF/Cr was found to have 87.5% sensitivity and 
100% specificity, and BDNF/Cr was found to have 
87.5% sensitivity and 83.3% specificity for OAB 
diagnosis. BDNF/Cr was more significant in 
treatment follow-up (decreased)22. In patients where 
there was no recurrence, urinary NGF/Cr decreased at 
the end of treatment in comparison to the baseline. 
This decreased level was maintained at 12 weeks after 
the end of treatment (P<0.05)24. Increased urinary 
NGF, BDNF, and ATP can help in identifying OAB 
phenotypes and choose patients for therapies directed 
to neurotrophic and purinergic pathways25. 
 
 
Fig. 1 — Signaling pathway of BDNF: Mature Brain derived 
neurotrophic factor (mBDNF) binds to Tyrosine kinase b ( TRKB) 
receptor → recruitment of proteins → activation of 3 signal 
transduction cascade → 1) sequential activation of IRS-1/2, PI-3K, 
Akt; 2) sequential activation of Shc/Grb2, Ras, Raf, MEKs, ERK; 3) 
activation of PLC, IP3, DAG, PKC. These signal transduction 
activates CREB and CREB-binding protein (CBP) → expression of 
genes encoding proteins involved in neural plasticity, stress resistance, 
and cell survival. [IRS-1/2 - Insulin receptor substrate-1, PI-3K -
phosphatidylinositol-3-kinase, Akt - protein kinase B, Shc - Science. 
Src homology 2 domain-containing a structural domain in signal 
transduction proteins, GRB2 - Growth factor receptor-bound protein 
2, RAF – Rapidly accelerated fibrosarcoma, MEK - mitogen-
activated protein kinase, ERK - extracellular signal regulated 
kinases, PLC - phospholipase C, IP3 - inositol (1,4,5)-trisphosphate, 
DAG – diacylglycerol, PKC - protein kinase C, CREB - cAMP-
response-element-binding protein. (This figure is adapted and 
modified from Bathina S & Das UN18.)  
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C-reactive protein  
C-Reactive Protein (CRP) is not a typical marker of 
the patho-physiological processes of OAB. It is a non-
specific marker of inflammation. Hence it has too 
poor sensitivity and specificity to become an isolated 
biomarker of OAB15. 
 
Cytokines 
Certain cytokines and chemokines are found 
relevant as a biomarker for overactive bladder. 
Chemokines are chemotactic cytokines. Most 
important chemokines causing chemotactic migration 
of macrophages, eosinophils, and mast cells are 
monocyte chemotactic protein 1 (MCP-1; CCL2), 
macrophage inflammatory protein (MIP-1; CCL4), 
and eotaxin (CCL1)26. There is a linear relationship 
between the severity of the patient’s OAB symptoms 
and the level of these urinary proteomics27. Urinary 
monocyte chemotactic protein 1 (MCP-1) is been 
studied in relation to OAB. It has been found that in 
female OAB patient urinary MCP-1 was very high in 
comparsion to the healthy individual. OAB-wet 
patients had a higher level in comparison to OAB-dry. 
Urinary MCP-1 levels measured by ELISA and 
normalised by urinary creatinine (Cr) levels28. More 
than 10-fold increase in the levels of MCP-1 and the 
soluble fraction of the CD40 ligand was seen in OAB 
patients in comparsion to control individuals. The 
five-fold increase was seen in the levels of MIP-1β, 
interleukin (IL)-12, p70/p40, IL-5, EGF, and growth 
related oncogene-A and a 3-fold increase was seen in 
soluble IL-2Ra, and IL-10 in compare to control 
individuals29. In female with OAB, there were 
increased levels of IL-8 and /or MCP-1 in the urine30. 
Contrary to the above mentioned findings, another 
study found a significantly lower level of urinary  
IL-10, IL-12p70, and IL-13 levels in OAB patients in 
comparison to control31. IL 1 corresponded with 
worsening symptom distress on UDI-6 (Urinary 
Distress Inventory Questionnaire 6). This observation 
has warranted for further in-depth study of these 
cytokines in OAB. 
Analysis of plasma by mesoscale discovery analysis 
revealed that 5 biomarkers (IL-4, TNF-α, MIP-1β, 
SAA, and Tie2) could significantly differentiate 
between OAB patients and control individuals. In OAB 
patients significantly lower value for IL-4, an anti-
inflammatory cytokine, and Tie2, tyrosine kinase 
receptor involved with angiogenesis were observed 
whereas, significantly higher value for TNF-α, a 
proinflammatory cytokine/chemokine, SAA,(Serum 
amyloid A) an acute phase apolipoprotein important for 
recruitment of immune cells to inflammatory sites and 
MIP-1β in compare to control were observed32. An 
animal study reported the protective effects of IL-4 on 
the bladder wall during inflammation and detrusor 
overactivity. Vector-mediated expression of IL-4 with 
irritated bladder wall resulted in decreased bladder 
overactivity, as well as decreased inflammatory 
response and nociceptive behaviour in comparison to 
the untreated bladder33. That means IL-4 have an anti-
inflammatory, protective effect on the bladder wall. 
The role of Tie2 in OAB is not properly known though 
its role in bladder carcinoma is well known - 
significantly lower than the control34 (Fig. 2).  
 
Prostaglandins 
Prostaglandins (PGs) increase the afferent signals 
of the micturition reflex, leading to the occurrence of 
OAB. Preclinical trials have revealed that PGs 
instilled into the urethra induces its relaxation; while 
intravesical instillation induces detrusor contraction20. 
Levels of PGE2 and PGF2α in the urine of OAB 
patients are considerably higher than in healthy 
individual36. Cyclooxygenase (COX) inhibitors 
improve DO due to cerebral infarction by suppressing 
peripheral C fibre’s without affecting urine 
production. The non-selective COX inhibitor is more 
 
Fig. 2 — Role of Interleukin in inflammation and repair
(Figure adapted and modified from Gieseck RL III et al.35) 
PAL & BANDYOPADHYAY: BIOMARKERS IN OVERACTIVE BLADDER 
 
 
149
efficient than the selective COX-1 or COX-2 inhibitor 
alone37. Hence PGs in the diagnosis of OAB is still 
had to go many more miles. 
 
Stem cell factor 
On immunohistochemical study c-kit ligand, stem 
cell factor (SCF) was found to be significantly more 
on overactive bladder than control38. Interstitial cells 
of Cajal (ICC) which is present in the gastro-intestinal 
tract, act as primary pacemaker cells that transmit 
depolarizing currents into neighbouring smooth 
muscles to start spontaneous slow waves and phasic 
contractions39. ICC expresses proto-oncogene c-kit, 
which is used as an identification marker for ICC40. In 
whole urinary tract starting from renal pelvis upto 
urethra c-kit positive ICCs are found – they are also 
called as interstitial cells (IC), ICC-like cells, or 
myofibroblasts41. In the urinary bladder ICCs may be 
responsible for signal transmission between smooth 
muscle bundles - from efferent nerves to muscles, and 
from urothelium to afferent nerves42. Now the stem 
cell factor gets bonded to ICCs via c-kit and affect the 
controlling of bladder function. In OAB patient 
median and IQRs of urinary SCF and SCF/Cr level 
was 85.9 pg/mL and 1.3 in compare to 18.9 pg/mL 
and 0.26 in control individuals38. 
 
mRNA expression 
mRNA expression of connexin (Cx) and transient 
receptor potential (TRP) channel on urothelial cells from 
urine was measured using quantitative real-time reverse 
transcription polymerase chain reaction. It revealed 
positive correlations Cx26 vs urgency score, Cx40 vs 
nocturia, TRPM2 (Transient receptor potential 
melastatin 2) vs intermittency, TRPV1 (Transient 
receptor potential cation channel subfamily V member 
1, also known as the capsaicin receptor and the vanilloid 
receptor 1) vs urgency incontinence, and negative 
correlation Cx40 vs intermittency43. In plasma of OAB 
patients up-regulation of let-7b-5p, miR-92a-3p, miR-
98-5p, miR-142-3p, and miR-200c-3p and down-
regulation of miR-139-5p was found. miR-98-5p 
showed the highest diagnostic accuracy alone 
(AUC = 0.79) in ROC curve analysis. Combined miR-
98-5p + miR-139-5p is seem to be a good indicator 
(AUC = 0.839). This knowledge may help in inventing 
drugs for OAB also44. Urinary bladder wall transfection 
of the miR-132 plasmid in absence of acetic acid 
exposure is independently able to induce overactivity, 
hypertrophy, and upregulation of NGF and other 
cytokines45. 
 
Conclusion  
Bladder inflammation and nerve growth factors are 
believed to be associated with OAB. BDNF, NGF, 
NGF/ Cr ratio, CRP, cytokines, prostaglandins, stem 
cell factors, mRNA expression of Cx and TRP channel 
on urothelial cells from urine are found to be 
associated with OAB. Five cytokines (IL-4, TNF-α, 
MIP-1β, SAA, and Tie2) in plasma significantly differ 
in OAB patients from healthy individuals. However, 
combined use of several biomarkers may yield a 
better level of sensitivity and specificity than a single 
one. New horizons are coming up regarding 
biomarkers of overactive bladder and some of them 
have the promise of helping in developing therapeutic 
agents. 
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